Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/ijms21093253
Keywords
non-coding RNA; microRNA; replacement therapy; antisense-mediated inhibition; mimicRNA; lung targeting; pulmonary disease; pulmonary hypertension; nanoparticle; liposome
Funding
- Ministerio de Economia, Industria y Competitividad (MEIC) [SAF2017-84494-C2-R]
- Gobierno Vasco, Dpto. Industria, Innovacion, Comercio y Turismo under the ELKARTEK Program [KK-2019/bmG19]
- BBVA Foundation (Ayudas a Equipos de investigacion cientifica Biomedicina 2018)
- Fundacion contra la Hipertension Pulmonar (2018)
- Maria de Maeztu Units of Excellence Programme-Ministry of Science, Innovation and Universities [MDM-2017-0720]
Ask authors/readers for more resources
In this review, the potential future role of microRNA-based therapies and their specific application in lung diseases is reported with special attention to pulmonary hypertension. Current limitations of these therapies will be pointed out in order to address the challenges that they need to face to reach clinical applications. In this context, the encapsulation of microRNA-based therapies in nanovectors has shown improvements as compared to chemically modified microRNAs toward enhanced stability, efficacy, reduced side effects, and local administration. All these concepts will contextualize in this review the recent achievements and expectations reported for the treatment of pulmonary hypertension.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
